Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nxera Pharma Co., Ltd. (4565.T)
Tokyo, JP
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.42% | +10.18% | +18.71% | +38.36% | +45.50% | +43.60% | +42.25% | -57.13% | -26.46% | -79.85% | -40.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+2.7% ★ Q1'26: +69.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-157.4% Q1'26: +302.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-37.0% Q1'26: -17.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-27.9% Q1'26: +31.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-8.4% ★ Q1'26: +7.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.6% ★ Q1'26: +16.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-14.68× Q1'26: 3.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.07B
est: 3.65B (-43.3%)
|
3.67B
est: 8.21B (-55.3%)
|
8.15B
est: 19.46B (-58.1%)
|
18.90B
est: 7.88B (+139.9%)
|
6.96B
est: 4.19B (+66.0%)
|
3.83B
est: 4.19B (-8.6%)
|
9.73B
est: 11.10B (-12.4%)
|
8.84B
est: 9.11B (-3.0%)
|
17.71B
est: 16.39B (+8.1%)
|
15.57B
est: 14.46B (+7.7%)
|
12.77B
est: 23.34B (-45.3%)
|
28.84B
est: 32.92B (-12.4%)
|
29.62B
est: 32.77B (-9.6%)
|
39.04B
34.82B – 44.21B
+19.1% YoY
|
38.63B
32.43B – 44.36B
-1.0% YoY
|
47.09B
46.55B – 47.63B
+21.9% YoY
|
45.32B
39.25B – 51.68B
-3.8% YoY
|
47.26B
40.93B – 53.89B
+4.3% YoY
|
| EBITDA |
651.62M
est: 196.74M (+231.2%)
|
1.13B
est: 442.74M (+155.5%)
|
1.85B
est: 1.05B (+76.5%)
|
13.05B
est: 424.74M (+2,972.7%)
|
-1.44B
est: 225.85M (-735.4%)
|
-6.03B
est: 225.85M (-2,770.2%)
|
2.46B
est: 598.26M (+310.9%)
|
2.20B
est: 491.27M (+348.4%)
|
8.19B
est: 883.29M (+826.8%)
|
4.16B
est: 779.15M (+433.5%)
|
-6.58B
est: 157.64M (-4,275.3%)
|
-1.38B
est: 222.33M (-720.7%)
|
-3.91B
est: 221.34M (-1,865.6%)
|
263.69M
235.19M – 298.61M
+19.1% YoY
|
260.92M
219.07M – 299.60M
-1.0% YoY
|
318.05M
314.40M – 321.69M
+21.9% YoY
|
306.12M
265.12M – 349.05M
-3.8% YoY
|
319.23M
276.48M – 364.00M
+4.3% YoY
|
| EBIT |
631.27M
est: -273.02M (+331.2%)
|
1.03B
est: -614.40M (+268.1%)
|
926.00M
est: -1.46B (+163.6%)
|
12.13B
est: -589.42M (+2,157.6%)
|
-2.46B
est: -313.42M (-685.8%)
|
-7.40B
est: -313.42M (-2,261.5%)
|
969.00M
est: -830.21M (+216.7%)
|
853.00M
est: -681.75M (+225.1%)
|
6.91B
est: -1.23B (+663.6%)
|
2.81B
est: -1.08B (+360.1%)
|
-9.06B
est: -2.82B (-221.1%)
|
-5.36B
est: -3.98B (-34.8%)
|
-8.27B
est: -3.96B (-108.8%)
|
-4.72B
-5.34B – -4.21B
-19.1% YoY
|
-4.67B
-5.36B – -3.92B
+1.0% YoY
|
-5.69B
-5.76B – -5.63B
-21.9% YoY
|
-5.48B
-6.25B – -4.75B
+3.8% YoY
|
-5.71B
-6.52B – -4.95B
-4.3% YoY
|
| Net Income |
1.53B
est: 3.85B (-60.4%)
|
516.00M
est: -4.53B (+111.4%)
|
-1.43B
est: 12.70B (-111.3%)
|
9.80B
est: -2.19B (+546.5%)
|
-2.65B
est: -5.93B (+55.2%)
|
-7.95B
est: -5.93B (-34.1%)
|
1.43B
est: 1.52B (-5.9%)
|
1.48B
est: 633.33M (+133.5%)
|
1.02B
est: 6.44B (-84.2%)
|
382.00M
est: 1.37B (-72.2%)
|
-7.19B
est: -9.84B (+26.9%)
|
-4.84B
est: -2.14B (-126.1%)
|
-12.53B
est: -799.91M (-1,466.4%)
|
3.40B
2.02B – 4.78B
+524.7% YoY
|
680.98M
-12.93B – 13.66B
-80.0% YoY
|
7.67B
829.16M – 19.42B
+1,026.0% YoY
|
5.37B
4.43B – 6.34B
-30.0% YoY
|
7.49B
6.19B – 8.86B
+39.6% YoY
|
| SGA |
875.96M
est: 1.63B (-46.1%)
|
1.94B
est: 3.66B (-46.9%)
|
2.48B
est: 8.67B (-71.4%)
|
2.73B
est: 3.51B (-22.3%)
|
4.48B
est: 1.87B (+140.0%)
|
2.23B
est: 1.87B (+19.7%)
|
2.55B
est: 4.95B (-48.5%)
|
2.53B
est: 4.06B (-37.8%)
|
3.14B
est: 7.30B (-57.0%)
|
3.54B
est: 6.44B (-45.1%)
|
6.85B
est: 8.68B (-21.1%)
|
11.68B
est: 12.24B (-4.6%)
|
15.23B
est: 12.19B (+24.9%)
|
14.52B
12.95B – 16.45B
+19.1% YoY
|
14.37B
12.07B – 16.50B
-1.0% YoY
|
17.52B
17.32B – 17.72B
+21.9% YoY
|
16.86B
14.60B – 19.22B
-3.8% YoY
|
17.58B
15.23B – 20.05B
+4.3% YoY
|
| EPS |
31.66
est: 42.93 (-26.2%)
|
9.38
est: -50.43 (+118.6%)
|
-23.39
est: 141.56 (-116.5%)
|
144.98
est: -24.45 (+692.9%)
|
-37.55
est: -66.05 (+43.2%)
|
-104.22
est: -66.05 (-57.8%)
|
18.69
est: 16.96 (+10.2%)
|
18.78
est: 7.06 (+166.1%)
|
12.53
est: 71.80 (-82.5%)
|
4.67
est: 15.28 (-69.4%)
|
-87.17
est: -113.99 (+23.5%)
|
-53.92
est: -23.61 (-128.4%)
|
-138.80
est: -8.82 (-1,472.9%)
|
36.25
22.36 – 52.91
+510.8% YoY
|
17.41
-143.22 – 151.28
-52.0% YoY
|
89.97
9.18 – 215.07
+416.9% YoY
|
59.44
49.09 – 70.27
-33.9% YoY
|
83.00
68.55 – 98.13
+39.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.03% | 1.87M | 0.39% |
| 2 | iShares MSCI Japan Small-Cap ETF SCJ | 0.03% | 82.1K | 0.50% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.03% | 179.0K | 0.58% |
| 4 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 233.0K | 0.40% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 840.4K | 0.06% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.87M | 0.06% |
| 7 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.01% | 28.4K | 0.83% |
| 8 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.01% | 1.71M | 0.40% |
| 9 | Amundi MSCI Disruptive Technology UCITS ETF Acc UNIC.L | 0.01% | 21.5K | 0.45% |
| 10 | iShares MSCI World Small-Cap ETF WSML | 0.01% | 71.7K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chris Cargill | Representative Executive Officer, President, CEO & Chairman | 252M | male |
| Shinichi Tamura | Founder | 233M | male |
| Hironoshin Nomura | Executive Officer & Chief Financial Officer | 92M | male |
| Candelle Chong | Executive Officer, Chief Executive Officer Office & Chief of Staff | 87M | female |
| Kieran Johnson | Executive Officer & Chief Accounting Officer | 83M | male |
| Shinya Tsuzuki | Head of Investor Relations | — | male |
| Toshihiro Maeda | President of Nxera Pharma Japan & Chief Operating Officer | — | male |
| Kazuhiko Yoshizumi | Executive Officer & Chief Compliance Officer | — | male |
| Mariko Nakafuji | Executive Vice President & Chief Legal Officer | — | female |
| Patrik Foerch | Chief Scientific Officer & President of Nxera Pharma UK | — | male |
| Shinichiro Nishishita | Vice President of Investor Relations & Head of Regulatory Disclosures | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4565.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
